Theseus Pharmaceuticals (NASDAQ:THRX) Now Covered by Analysts at Stifel Nicolaus

Posted by Defense World Staff on Mar 17th, 2023

Equities research analysts at Stifel Nicolaus initiated coverage on shares of Theseus Pharmaceuticals (NASDAQ:THRX – Get Rating) in a report issued on Wednesday, The Fly reports. The firm set a “buy” rating and a $24.00 price target on the stock. Stifel Nicolaus’ price target suggests a potential upside of 207.69% from the company’s current price.

A number of other equities research analysts also recently weighed in on THRX. Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Theseus Pharmaceuticals in a research report on Friday, March 10th. HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of Theseus Pharmaceuticals in a research report on Friday, March 10th.

Theseus Pharmaceuticals Trading Up 6.1 %

Shares of NASDAQ THRX opened at $7.80 on Wednesday. The stock has a 50 day simple moving average of $10.46 and a 200-day simple moving average of $7.62. The company has a market cap of $339.77 million, a PE ratio of -6.00 and a beta of 4.25. Theseus Pharmaceuticals has a 12-month low of $4.01 and a 12-month high of $15.21.

Theseus Pharmaceuticals (NASDAQ:THRX – Get Rating) last issued its quarterly earnings data on Thursday, March 9th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.09. Sell-side analysts forecast that Theseus Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Theseus Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Foresite Capital Management V LLC raised its stake in Theseus Pharmaceuticals by 7.5% during the 4th quarter. Foresite Capital Management V LLC now owns 3,585,346 shares of the company’s stock valued at $17,855,000 after purchasing an additional 250,000 shares during the period. Frazier Life Sciences Management L.P. acquired a new position in shares of Theseus Pharmaceuticals in the fourth quarter worth $6,963,000. BlackRock Inc. increased its stake in shares of Theseus Pharmaceuticals by 12.8% in the third quarter. BlackRock Inc. now owns 775,590 shares of the company’s stock worth $4,499,000 after acquiring an additional 88,231 shares during the last quarter. Opaleye Management Inc. increased its stake in shares of Theseus Pharmaceuticals by 142.5% in the fourth quarter. Opaleye Management Inc. now owns 535,000 shares of the company’s stock worth $2,664,000 after acquiring an additional 314,350 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Theseus Pharmaceuticals by 4.2% in the fourth quarter. Geode Capital Management LLC now owns 299,606 shares of the company’s stock worth $1,492,000 after acquiring an additional 12,211 shares during the last quarter. Institutional investors and hedge funds own 85.22% of the company’s stock.

About Theseus Pharmaceuticals

(Get Rating)

Theseus Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial.